News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase I Clinical Study Of Neumedicines Inc.' Interleukin-12 As A Treatment For Wound Healing And Infections Recommended For Funding By The U.S. Department Of Defense


4/28/2014 11:06:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held biotechnology company, announced today that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES